Dubininskaya str. 57, bld.1, 115054, Moscow, Russia
info@regapharm.com

+7(499)517-95-23

Main  >  News  >  Guidelines for determining the scope of laboratory tests for registration of drugs in the EAEU are presented

Guidelines for determining the scope of laboratory tests for registration of drugs in the EAEU are presented

13 September 13, 2019 on the EAEU legal portal docs.eaeunion.org published Recommendation of the EEC Board No. 28 “On the Guidelines for Determining the Scope of Laboratory Tests in the Examination of Medicines”. Document adopted on September 10, 2019.

According to the information provided, member states of the Eurasian Economic Union, starting from the date of publication of this Recommendation, should use this Guide when determining the scope of laboratory tests during registration, confirmation of registration and amendments to the registration dossier of a drug.

The document states that the provision of samples, specific reagents and other materials is not required if it is not possible to conduct tests in an expert organization due to the inaccessibility of drug samples (including when they are classified as orphan, narcotic, psychotropic, radiopharmaceutical or intended for the treatment of high-cost nosologies due to their high cost), the inability to comply with the conditions for the transportation of these samples to the customs territory of  member states of the EAEC and (or) storage, without special equipment and consumables in an expert organization. In these cases, laboratory tests are conducted in the quality control laboratory of the manufacturer of the drug in the presence of representatives of the expert organization or in the contract laboratory used by the manufacturer in the presence of representatives of the expert organization.

Make request

Your name

Your phone

Your email (required)

Choose the topic of your message

Your message